Lobbying Update: $570,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed

$570,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Supply Chain - advocacy efforts on topics that could potentially impact the medical device supply chain such as decisions made by the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party, outbound investments, raw materials, components, export controls, and shortage/supply chain resiliency reporting regulations. EPA Rulemaking Restricting Ethylene Oxide (ETO) - Proposed rulemaking to place more-stringent limits on emissions and institute new monitoring requirements for ethylene oxide (ETO). Advocacy efforts include educating lawmakers on the importance of ETO in the sterilization of medical devices and potential shortages of sterile medical devices if EPA's proposed changes are enacted. FY2026 National Defense Authorization Act (NDAA) (H.R. 3838/S.2296) - Section 863 of H.R. 3838: Requirement for Contractors to Provide Reasonable Access to Repair Materials If enacted this legislation would enforce an expansive right to repair (RTR) policy on any businesses that contract with the Department of War, mandating that manufacturers provide access to proprietary data and tools. We are engaging in advocacy efforts to have the provision in the House bill removed from the final legislation, and educating lawmakers on the critical role of the Food and Drug Administration in maintaining product safety and effectiveness throughout the device lifecycle in addition to the potential risks associated with third-party servicing of medical technologies. Medical device procurement and supply chain resiliency. Ensuring VHA patient access to Med Tech as VHA manages supply chain and upgrades its medical surgery and prosthetics procurement contracting. Pain management - working to increase veteran access to multidisciplinary and multimodal pain management to provide for effective non-opioid treatment alternatives. VA Authorization Bill of 2025- Specifically provisions to streamline product procurement and the purchase order processes. OECD 2 Pillar Framework Implementation - International tax provisions specifically regarding the global minimum tax, including the Defending American Jobs Act (H.R. 591) and the Unfair Tax Prevention Act (H.R.2423), legislation regarding extraterritorial taxation. H.R. 1990 American Innovation and R&D Competitiveness Act of 2025. To restore immediate tax deductions for research and development (R&D) expenses, reversing the requirement that companies amortize these costs over several years. H.R. 1 (and Senate Amendment 2360) The One Big Beautiful Bill Act- Maintaining the International Tax regime as established in the 2017 TCJA legislation. Policies include proposed changes to GILTI, specifically Country by Country Reporting, the Section 250 deduction, Roundtripping, Section 899, and to return to pre-2022 R&D expensing rules. Ensuring Patient Access to Critical Breakthrough Products Act of 2025(H.R. 5343 and S.1717) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. (CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET) - advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization.) The Patient Access to Innovative New Technologies Act (PAINT Act) -- proposed legislation that aims to expand access to new medical technologies by improving the Medicare New Technology Add-on Payment (NTAP) program. It would create a single deadline for products in an alternative pathway, ensure breakthrough devices are eligible for conditional approval under NTAP, and prevent disruption in Medicare beneficiaries' access to new treatments. 2025 Reauthorization of the SUPPORT for Patients and Communities Act - Advocacy for reauthorization of the SUPPORT Act, specifically for FDA approved alternative treatments for Chronic Pain, and medical devices role to address the opioid epidemic. Starting work on the Food and Drug Omnibus Reform Act of 2026 (Public Law 117-328) - advocacy efforts on Medical Device User Fee Amendments (MDUFA) reauthorization, riders, and device shortages. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) (Public Law 109-417) - advocacy on risk mitigation plans and voluntary shortage reporting related to medical device supply chains and advocacy for medical research and to foster a new era of medical innovation and prepare for future pandemics and promote health equity. Support passage of the Radiation Oncology Case Rate (ROCR) Value Based Payment Program Act of 2025 - Senate (S. 1031) & (H.R. 2120). This legislation would increase access to patient care, enhance the quality of cancer treatments, encourage innovation, reduce disparities for rural and underserved patients, and lower patient costs by saving Medicare about $200 million over 10 years."

You can find more data on corporate lobbying on Quiver Quantitative.

BSX Congressional Stock Trading

Members of Congress have traded $BSX stock 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:

• REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
• REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/04.
• REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 07/31, 06/26, 06/11, 05/13, 04/28.
• REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
• REPRESENTATIVE BRUCE WESTERMAN sold up to $15,000 on 04/21.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

BSX Insider Trading Activity

BSX insiders have traded $BSX stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:

• MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 4 sales selling 328,886 shares for an estimated $33,903,109.
• JOSEPH MICHAEL FITZGERALD (EVP & Group Pres, Cardiology) has made 0 purchases and 7 sales selling 256,372 shares for an estimated $26,574,358.
• ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) has made 0 purchases and 2 sales selling 34,627 shares for an estimated $3,578,501.
• VANCE R BROWN (SVP, GC and Corp. Secretary) has made 0 purchases and 2 sales selling 9,652 shares for an estimated $972,487.
• EDWARD J LUDWIG has made 0 purchases and 2 sales selling 8,000 shares for an estimated $842,488.
• JOHN BRADLEY SORENSON (EVP, Global Operations) sold 4,572 shares for an estimated $477,956
• YOSHIAKI FUJIMORI sold 2,901 shares for an estimated $310,377

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

BSX Hedge Fund Activity

We have seen 863 institutional investors add shares of BSX stock to their portfolio, and 647 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• FMR LLC removed 20,286,637 shares (-15.8%) from their portfolio in Q2 2025, for an estimated $2,178,987,680
• EDGEWOOD MANAGEMENT LLC added 6,951,450 shares (+inf%) to their portfolio in Q2 2025, for an estimated $746,655,244
• JPMORGAN CHASE & CO removed 5,862,792 shares (-18.6%) from their portfolio in Q2 2025, for an estimated $629,722,488
• BLACKROCK, INC. added 5,016,674 shares (+3.5%) to their portfolio in Q2 2025, for an estimated $538,840,954
• VOYA INVESTMENT MANAGEMENT LLC removed 4,362,310 shares (-49.9%) from their portfolio in Q3 2025, for an estimated $425,892,325
• MILLENNIUM MANAGEMENT LLC removed 3,708,137 shares (-44.4%) from their portfolio in Q2 2025, for an estimated $398,290,995
• MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 3,662,461 shares (-22.2%) from their portfolio in Q2 2025, for an estimated $393,384,936

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

BSX Analyst Ratings

Wall Street analysts have issued reports on $BSX in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• Needham issued a "Buy" rating on 10/17/2025
• Evercore ISI Group issued a "Outperform" rating on 10/07/2025
• Canaccord Genuity issued a "Buy" rating on 10/01/2025
• Leerink Partners issued a "Outperform" rating on 10/01/2025
• BTIG issued a "Buy" rating on 10/01/2025
• Truist Securities issued a "Buy" rating on 10/01/2025
• Baird issued a "Outperform" rating on 10/01/2025

To track analyst ratings and price targets for BSX, check out Quiver Quantitative's $BSX forecast page.

BSX Price Targets

Multiple analysts have issued price targets for $BSX recently. We have seen 15 analysts offer price targets for $BSX in the last 6 months, with a median target of $125.0.

Here are some recent targets:

• Mike Matson from Needham set a target price of $121.0 on 10/17/2025
• Vijay Kumar from Evercore ISI Group set a target price of $110.0 on 10/07/2025
• Matt Miksic from Barclays set a target price of $136.0 on 10/02/2025
• Richard Newitter from Truist Securities set a target price of $129.0 on 10/01/2025
• David Rescott from Baird set a target price of $128.0 on 10/01/2025
• William Plovanic from Canaccord Genuity set a target price of $132.0 on 10/01/2025
• Mike Kratky from Leerink Partners set a target price of $128.0 on 10/01/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.